New drug cocktail aims to control mantle cell lymphoma without chemo
NCT ID NCT06522386
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This Phase 2 trial is testing a combination of three drugs—pirtobrutinib, rituximab, and venetoclax—in 50 adults with untreated mantle cell lymphoma. The goal is to see how many patients achieve a complete response (no signs of cancer) after the combination therapy. Researchers are also monitoring side effects. This approach aims to control the disease without traditional chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55902, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirtobrutinib, rituximab, and venetoclax
What this could lead to
If successful, this combination could offer a highly effective, chemotherapy-free option for newly diagnosed mantle cell lymphoma, potentially leading to long-term disease control.
What could go wrong
This is an early-phase (Phase 2) trial with only 50 participants, so results may not apply to all patients. Side effects from the drug combination could be significant, and the treatment is not expected to be a cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.